Recruiting
18+ years
Male or Female
NCT03533283

An Open-Label Phase lB Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Belgium
  • UZ Gent
Denmark
  • Rigshospitalet; Fase 1 Enhed
Italy
  • Istituto Nazionale Tumori Irccs Fondazione
  • Policlinico S.Orsola-Malpighi;Istituto di Ematologia "Seragnoli"
  • ASST PAPA GIOVANNI XXIII
  • Fond. IRCCS Istituto Nazionale Tumori
Spain
  • Hospital Universitari Vall d'Hebron
  • Hospital Duran i Reynals
  • HOSPITAL DE MADRID NORTE SANCHINARRO
  • Hospital Clinico Universitario Virgen de la Victoria
  • Hospital Clinico Universitario de Valencia
UK
  • The HOPE Clinical Trials Unit
  • University College London Hospitals NHS Foundation Trust
  • The Newcastle upon Tyne Hospitals NHS Foundation Trust
This is an open-label, single arm, multicenter, dose finding, Phase Ib study in order to assess the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) for this combination treatment and to evaluate the general safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and preliminary anti-tumor activity of this combination treatment in adult patients. This study includes an additional open-label imaging feasibility sub-study using a tracer in adult participants with relpased/refractory B-cell non-Hodgkin's lymphoma to image CD8+T-cells at baseline and after treatment with glofitamab, including pre-treatment with obinutuzumab.
Not Yet Recruiting
50+ years
Male or Female
NCT04874818

CD8+ T-cell PET/CT Imaging in COVID-19 Patients (Tangelo)

Netherlands
  • Radboud University Medical Center
A subset of patients diagnosed with severe acute respiratory syndrome (SARS)-CoV2 infection present with lymphopenia. The degree of lymphopenia, and in particular reduced cluster of differentiation (CD)8+ T-cell numbers, is correlated with clinical deterioration and intensive care unit (ICU) admission. The underlying reasons for lymphopenia in coronavirus disease (COVID)-19 is currently unclear, We aim to assess differences in the in vivo distribution of CD8+ T-cells in patients with proven SARS-CoV2 presenting with lymphopenia or with normal lymphocyte counts, using Zirconium-89 ([89Zr])Df-IAB22M2C positron emission tomography (PET) imaging.
Not Yet Recruiting
18+ years
Male or Female
NCT04826393

ASP8374 + Cemiplimab in Recurrent Glioma

United States
  • Brigham and Women's Hospital
This study is looking at the safety and efficacy of the drug combination of ASP8374 with cemiplimab in people with recurrent malignant glioma. The study will be conducted in two parts, the first portion of the study will be to establish the highest dose of ASP8374 that can be given safely with cemiplimab and will be used as the recommended dose of ASP8374 in combination with cemiplimab for the second portion of the study. The second portion of the study will be to compare the effect of having ASP8374 in combination with cemiplimab prior to surgery. The names of the study drugs involved in this study are: ASP8374; Cemiplimab; 89Zr-Df-IAB22M2C (Administered as part of scan procedure)
Completed
18+ years
Male or Female
NCT03107663

⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma

United States
  • Memorial Sloan Kettering Cancer Center
  • University of Pennsylvania
  • Honor Health and Imaging Endpoints
To determine the safety and feasibility of 89Zr-Df-IAB22M2C as an immunoPET tracer; determine the best time window and protein dose for imaging; determine the pharmacokinetic (PK) and biodistribution of the probe; and to determine imaging parameters for optimal lymphoid and tumor visualization.
Recruiting
18+ years
Male or Female
NCT03802123

⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors

United States
  • University of Alabama-Birmingham Hospital
  • CARTI Cancer Center
  • City of Hope National Medical Center
  • University of Iowa Hospitals and Clinics
  • Dana-Farber Cancer Institute
  • Karmanos Cancer Institute
  • Washington University School of Medicine
  • Memorial Sloan Kettering Cancer Center
  • Oregon Health& Science University
  • University of Pennsylvania
Protocol IAB-CD8-201 is a Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Advanced or Metastatic Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck Selected to Receive Standard-of-Care Immunotherapy as Single Agent or in Combination. This study will evaluate the safety of repeat doses of ⁸⁹Zr-Df-IAB22M2C, assess and quantify any detectable changes in ⁸⁹Zr-Df-IAB22M2C uptake from Baseline to post-Treatment, establish the relationship of ⁸⁹Zr-Df-IAB22M2C uptake in tumors with CD8+ TIL density, biodistribution, evaluate the variance in participants' gene expression pre- and post-Treatment, evaluate the correlation of ⁸⁹Zr-Df-IAB22M2C uptake with clinical response by RECIST 1.1/iRECIST and evaluate the correlation of ⁸⁹Zr-Df-IAB22M2C uptake with immune infiltrates and other molecular biomarkers (CD4, CD8, PD-1 and PD-L1) expression by IHC.